We evaluated GCGMM using a retrospectively collected 75 invasive ductal carcinoma with ERPR+ HER2− (n = 15), triple negative (TN) (n = 9), and ER-HER2+ (n = 57) cancers with variable presentation (mass and non-mass enhancement) and background parenchymal enhancement (mild and marked). Here, ERBB2 is linked to cancer.